A 75-Year-Old Male Develops Painful Erythema Around His Nails After Starting Treatment

Poll

A 75-year-old male patient develops painful erythema around his nails 10 weeks after starting cancer treatment. Which medication is most likely responsible?

A 75-year-old male patient develops painful erythema around his nails 10 weeks after starting cancer treatment. According to the image below, which medication is most likely responsible?

Image courtesy of Shivani V. Tripathi, M.D.  and  Milan J. Anadkat, M.D.

What is your diagnosis?

A. Cyclophosphamide
B. Cetuximab
C. Docetaxel
D. Hydroxyurea
Related Videos
Rahul Gosain, MD; Sam Klempner, MD; and Rohit Gosain, MD, presenting slides
Rahul Gosain, MD; Sam Klempner, MD; and Rohit Gosain, MD, presenting slides
Rahul Gosain, MD; Sam Klempner, MD; and Rohit Gosain, MD, presenting slides
Rahul Gosain, MD; Sam Klempner, MD; and Rohit Gosain, MD, presenting slides
Related Content
Nogapendekin alfa-inbakicept is now approved for the treatment of patients with BCG-unresponsive non-muscle invasive bladder cancer.

FDA Approves Nogapendekin Alfa-inbakicept/BCG in BCG-unresponsive NMIBC

April 22nd 2024
Article

Nogapendekin alfa-inbakicept is now approved for the treatment of patients with BCG-unresponsive non-muscle invasive bladder cancer.

Richard Lazzaro, MD, discusses how a robot-assisted platform has impacted his thoracic surgery and highlights other potential advancements in the field.

Moving The Needle in Lung Cancer Management With Robotic-Assisted Surgery

April 22nd 2024
Podcast

Richard Lazzaro, MD, discusses how a robot-assisted platform has impacted his thoracic surgery and highlights other potential advancements in the field.

7-Gene Predictive Biosignature Helps Predict Ipsilateral Breast Cancer Recurrence

7-Gene Predictive Biosignature Helps Predict Ipsilateral Breast Cancer Recurrence

April 22nd 2024
Article

DCISionRT is a risk-assessment test for patients designed to predict RT benefit and develop their recurrence risk after surgery alone or with radiation.

Experts discuss findings related to gastrointestinal cancer outcomes as well as treatment inequalities presented at the 2024 SSO Annual Meeting.

Surgeons Talk Key Treatment and Institutional Advances Across Oncology Care

April 15th 2024
Podcast

Experts discuss findings related to gastrointestinal cancer outcomes as well as treatment inequalities presented at the 2024 SSO Annual Meeting.

69 The Importance of Tri-Modality Therapy for De Novo Stage IV Invasive Lobular Carcinoma (ILC) Presenting With Bone-Only Metastases

69 The Importance of Tri-Modality Therapy for De Novo Stage IV Invasive Lobular Carcinoma (ILC) Presenting With Bone-Only Metastases

April 21st 2024
Article
70 Navigating Lymphedema: The Impact of Indocyanine Green Lymphography (ICG_L) on Personalized Therapy Outcomes in Patients With Breast Cancer (BC)

70 Navigating Lymphedema: The Impact of Indocyanine Green Lymphography (ICG_L) on Personalized Therapy Outcomes in Patients With Breast Cancer (BC)

April 20th 2024
Article